CRISPR Therapeutics Stock Experiences Volatility Amid Commercialization Challenges

CRISPR Therapeutics (NASDAQ: CRSP) has experienced significant stock volatility this year as investors assess its transition from a clinical-stage to commercial-stage biotech company. Despite the approval of CASGEVY in late 2023, revenue remains low at $1.46 million for Q1 2026 with a net loss of $122.9 million.

By Jeff Siegel, The Motley Fool Thu, June 18, 2026 at 4:20 PM GMT+3 4 min read · Yahoo Finance · June 18, 2026, 13:20 UTC

Tickers: $CRSP $VRTX

Topics: commercialization progress CRISPR Therapeutics gene-editing therapies stock volatility

Read the full article at Yahoo Finance

More World news

Nvidia CEO Jensen Huang Resigns Amid Personal Scandals and National Security Allegations CNBC · November 12, 2026, 13:51 UTC
Zenta Group Receives Nasdaq Notice Regarding Minimum Bid Price Requirement Seeking Alpha · November 12, 2026, 13:48 UTC
SoLo Funds Launches SoLo Alpha High-Yield Investment Account PR Newswire · November 12, 2026, 13:50 UTC
Artelo Biosciences Reports Third Quarter GAAP EPS of -$3.19 Seeking Alpha · November 12, 2026, 13:46 UTC
Monopar Therapeutics Reports Q3 GAAP EPS of -$0.72 in Line with Expectations Seeking Alpha · November 12, 2026, 13:48 UTC
Market Watch: Nvidia Pressure and Key Stocks NBIS, GOOG, GIS, and MANU Seeking Alpha · November 12, 2026, 13:48 UTC
Chevron Reports $10.4 Billion Third Quarter Profit Driven by High Refining Margins Motley Fool · November 12, 2026, 13:43 UTC
Replay Sports Cards Expands North Carolina Presence with New Greenville Location PR Newswire · November 12, 2026, 13:47 UTC
Linnworks Survey Reveals US E-commerce Businesses Limit AI Role to Operational Support Over Financial Control PR Newswire · November 12, 2026, 13:43 UTC
DocsInk Rebrands as TraceWell Health and Launches Integrated Care Platform PR Newswire · November 12, 2026, 13:44 UTC